EWTX Q3 2025 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$47M

Net Income

-$41M

EPS (Diluted)

$-0.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$583M

Total Liabilities

$25M

Stockholders' Equity

$559M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$47M	-$40M	-15.9%
Net Income	-$41M	-$34M	-19.2%